Drugs for Acute Treatment of Migraine
Drugs for Acute Treatment of Migraine
September 14, 2026 (Issue: 1763)
Treatment of migraine headache pain when it is still mild
to moderate in intensity improves response and reduces
the risk of recurrence. An oral nonopioid analgesic such
as a nonsteroidal anti-inflammatory drug (NSAID) or
acetaminophen is often...more
- A Qaseem et al. Pharmacologic treatments of acute episodic migraine headache in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med 2025; 178:571. doi:10.7326/annals-24-03095
- G Gartlehner et al. Pharmacologic treatment of acute attacks of episodic migraine: a systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 2025; 178:507. doi:10.7326/annals-24-02034
- P Barbanti et al. The role of the combination paracetamol/caffeine in treatment of acute migraine pain: a narrative review. Pain Ther 2024; 13:319. doi:10.1007/s40122-024-00581-x
- HC Diener et al. Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: a systemic review and meta-analysis of randomized placebo-controlled trials. Eur J Neurol 2022; 29:350. doi:10.1111/ene.15103
- J Robblee et al. 2025 guideline update to acute treatment of migraine for adults in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache 2026; 66:53. doi:10.1111/head.70016
- S Alwan et al. Paracetamol use in pregnancy – caution over causal inference from available data. Nat Rev Endocrinol 2022; 18:190. doi:10.1038/s41574-021-00606-x
- Prenatal acetaminophen use and autism. Med Lett Drugs Ther 2025; 67:193.
- American College of Obstetricians and Gynecologists. ACOG affirms safety and benefits of acetaminophen during pregnancy. September 22, 2025. Available at: https://bit.ly/3W8XtGh. Accessed August 27, 2026.
- In brief: New warnings on NSAID use in pregnancy. Med Lett Drugs Ther 2020; 62:175.
- CJ Derry et al. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 5:CD009108. doi:10.1002/14651858.cd009108.pub2
- A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. Med Lett Drugs Ther 2025; 67:68.
- G Roberto et al. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 2014; 34:5. doi:10.1177/0333102413499649
- Y Orlova et al. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018; 75:566. doi:10.1001/jamaneurol.2017.5144
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- A Marchenko et al. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 2015; 55:490. doi:10.1111/head.12500
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Available at: https://bit.ly/3MjOzAs. Accessed August 27, 2026.
- Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:35.
- Rimegepant (Nurtec ODT) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:70.
- Zavegepant (Zavzpret) for acute treatment of migraine. Med Lett Drugs Ther 2023; 65:116.
- WK Karlsson et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ 2024; 386:e080107. doi:10.1136/bmj-2024-080107
- RB Lipton et al. Integrating gepants into clinical practice for the acute treatment of migraine. Headache 2026; 66:976. doi:10.1111/head.70047
- H Gosalia et al. Medication-overuse headache: a narrative review. J Headache Pain 2024; 25:89. doi:10.1186/s10194-024-01755-w
- M Ashina et al. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: a randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia 2025; 45: 3331024251395298. doi:10.1177/03331024251395298
- DW Dodick et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet 2023; 402:2307. doi:10.1016/s0140-6736(23)01683-5
- D Croteau et al. Arterial hypertension: a safety risk of calcitonin gene-related peptide ligand and receptor blocker class. Headache 2026; 66:1342. doi:10.1111/head.70089
- A new dihydroergotamine nasal spray (Trudhesa) for migraine. Med Lett Drugs Ther 2021; 63:204.
- A dihydroergotamine autoinjector (Brekiya) for migraine. Med Lett Drugs Ther 2025; 67:206.
- MJ Marmura et al. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55:3. doi:10.1111/head.12499
- RL Woosley et al. QT drugs list, AZCERT, Tucson, AZ. Available at: www.crediblemeds.org. Accessed August 27, 2026.
- PJ Goadsby et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology 2024; 103:e209584. doi:10.1212/wnl.0000000000209584
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Acute Treatment of Migraine
Article code: 1763a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
